BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Expected to Earn Q1 2025 Earnings of $0.59 Per Share

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Investment analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of BioMarin Pharmaceutical in a report released on Monday, September 16th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $0.59 for the quarter, up from their previous estimate of $0.57. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $2.40 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's Q3 2025 earnings at $0.65 EPS, Q1 2026 earnings at $0.73 EPS and Q2 2026 earnings at $0.80 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its earnings results on Monday, August 5th. The biotechnology company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.38 by $0.39. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. The firm had revenue of $712.03 million for the quarter, compared to analyst estimates of $660.51 million.

Several other analysts have also commented on BMRN. Stifel Nicolaus dropped their price target on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a "buy" rating on the stock in a research report on Tuesday. Barclays cut their price target on BioMarin Pharmaceutical from $111.00 to $110.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Scotiabank lowered their price target on BioMarin Pharmaceutical from $95.00 to $78.00 and set a "sector perform" rating on the stock in a research report on Tuesday. Sanford C. Bernstein cut their price objective on BioMarin Pharmaceutical from $116.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, TD Cowen decreased their target price on BioMarin Pharmaceutical from $125.00 to $120.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $98.84.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN traded up $0.27 during midday trading on Thursday, reaching $71.41. 2,934,332 shares of the stock were exchanged, compared to its average volume of 1,908,401. The company has a quick ratio of 1.95, a current ratio of 3.05 and a debt-to-equity ratio of 0.11. The firm has a market cap of $13.56 billion, a price-to-earnings ratio of 66.49, a PEG ratio of 1.03 and a beta of 0.32. The firm has a 50-day simple moving average of $86.11 and a two-hundred day simple moving average of $84.49. BioMarin Pharmaceutical has a twelve month low of $68.83 and a twelve month high of $99.56.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. AMI Asset Management Corp lifted its holdings in BioMarin Pharmaceutical by 51.9% in the first quarter. AMI Asset Management Corp now owns 346,189 shares of the biotechnology company's stock valued at $30,236,000 after acquiring an additional 118,230 shares during the last quarter. AGF Management Ltd. purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth $2,563,000. Fisher Asset Management LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 4th quarter worth about $1,301,000. APG Asset Management US Inc. purchased a new stake in BioMarin Pharmaceutical in the 4th quarter valued at about $3,462,000. Finally, Bridgewater Associates LP lifted its position in BioMarin Pharmaceutical by 18.3% in the fourth quarter. Bridgewater Associates LP now owns 190,970 shares of the biotechnology company's stock valued at $18,413,000 after buying an additional 29,576 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.